ERBB3 and ovarian carcinoma: In regard to ovarian cancer and ErbB3 for example, the randomized phase 2 trial of the anti-ErbB3 molecule seribantumab in combination with paclitaxel in patients with advanced platinum-resistant or refractory ovarian cancer showed an increased treatment benefit for patients whose tumors had detectable HRG mRNA and low HER29.